TRH therapy is used in several neurologic disorders, including spinocerebellar ataxia (SCA) where the improvement of ataxic gait is one of the important pharmacological responses (Sobue et al., 1983; Urayama, Yamada, Kimura, Zhang, & Watanabe, 2002). The gene discussed is TRH; the disease is autosomal dominant cerebellar ataxia.